Create Account | Sign In: Author or Forum

 
 
News  |  Journals  |  Conferences  |  Blogs  |  Articles  |  Forums  |  Twitter    
 

 Headlines:

 

Category: Family Medicine | Infections | Internal Medicine | Journal

Back to Journal Articles

Safe Dengue Vaccine Deemed Feasible

Last Updated: September 11, 2012.

 

Phase 2b study shows recombinant, live, attenuated tetravalent vaccine is well tolerated

Share |

Comments: (0)

Tell-a-Friend

 

  Related
 
A safe recombinant, live, attenuated tetravalent dengue vaccine has been deemed possible, according to a study published online Sept. 11 in The Lancet.

TUESDAY, Sept. 11 (HealthDay News) -- A safe recombinant, live, attenuated tetravalent dengue vaccine has been deemed possible, according to a study published online Sept. 11 in The Lancet.

Arunee Sabchareon, M.D., from Mahidol University in Bangkok, and colleagues conducted an observer-masked, randomized, controlled, phase 2b, proof-of-concept trial in healthy Thai schoolchildren, aged 4 to 11 years, to examine the efficacy of a recombinant, live, attenuated tetravalent dengue vaccine. Participants were randomly allocated to receive three injections of dengue vaccine (2,669 children; 2,452 children included in primary analysis), or control (rabies vaccine or placebo: 1,333 children; 1,221 children included in primary analysis) at zero, six, and 12 months, and were followed for 25 months.

The researchers found that there were 134 cases of virologically confirmed dengue. The vaccine protective efficacy against virologically confirmed dengue was 30.2 percent, and differed according to serotype. The vaccine was well tolerated; two years after the first dose, no evidence of safety signals was observed.

"Our study constitutes the first ever demonstration that a safe dengue vaccine is possible," the authors write. "In the context of World Health Organization goals to reduce dengue mortality by at least 50 percent and the morbidity rate by at least 25 percent by 2020, this study represents a major milestone."

Several authors are employed by and disclosed financial ties to Sanofi Pasteur, which funded the study.

Abstract
Full Text (subscription or payment may be required)
Editorial (subscription or payment may be required)

Copyright © 2012 HealthDay. All rights reserved.


Previous: PTSD Seen in Nearly 20 Percent of Young Children With Cancer Next: Gestational Diabetes, Poverty Link to ADHD Strengthened

Reader comments on this article are listed below. Review our comments policy.


Submit your opinion:

Name:

Email:

Location:

URL:

Remember my personal information

Notify me of follow-up comments?

advertisement.gif (61x7 -- 0 bytes)
 

Are you a Doctor, Pharmacist, PA or a Nurse?

Join the Doctors Lounge online medical community

  • Editorial activities: Publish, peer review, edit online articles.

  • Ask a Doctor Teams: Respond to patient questions and discuss challenging presentations with other members.

Doctors Lounge Membership Application

 
     

 advertisement.gif (61x7 -- 0 bytes)

 

 

Useful Sites
MediLexicon
  Tools & Services: Follow DoctorsLounge on Twitter Follow us on Twitter | RSS News | Newsletter | Contact us
Copyright © 2001-2014
Doctors Lounge.
All rights reserved.

Medical Reference:
Diseases | Symptoms
Drugs | Labs | Procedures
Software | Tutorials

Advertising
Links | Humor
Forum Archive
CME | Conferences

Privacy Statement
Terms & Conditions
Editorial Board
About us | Email

This website is certified by Health On the Net Foundation. Click to verify. This site complies with the HONcode standard for trustworthy health information:
verify here.